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Abstract
Background: Hepatitis C virus (HCV) is a blood-borne flavivirus that infects many millions of people worldwide.
Relatively little is known, however, concerning the stability of HCV and reliable procedures for inactivating this
virus.
Methods: In the current study, the thermostability of cell culture-derived HCV (HCVcc, JFH-1 strain) under different
environmental temperatures (37°C, room temperature, and 4°C) and the ability of heat, UVC light irradiation, and
aldehyde and detergent treatments to inactivate HCVcc were evaluated. The infectious titers of treated viral
samples were determined by focus-forming unit (FFU) assay using an indirect immunofluorescence assay for HCV
NS3 in hepatoma Huh7-25-CD81 cells highly permissive for HCVcc infection. MTT cytotoxicity assay was performed
to determine the concentrations of aldehydes or detergents at which they were no longer cytotoxic.
Results: HCVcc in culture medium was found to survive 37°C and room temperature (RT, 25 ± 2°C) for 2 and 16
days, respectively, while the virus was relatively stable at 4°C without drastic loss of infectivity for at least 6 weeks.
HCVcc in culture medium was sensitive to heat and could be inactivated in 8 and 4 min when incubated at 60°C
and 65°C, respectively. However, at 56°C, 40 min were required to eliminate HCVcc infectivity. Addition of normal
human serum to HCVcc did not significantly alter viral stability at RT or its susceptibility to heat. UVC light
irradiation (wavelength = 253.7 nm) with an intensity of 450 μW/cm
2 efficiently inactivated HCVcc within 2 min.
Exposures to formaldehyde, glutaraldehyde, ionic or nonionic detergents all destroyed HCVcc infectivity effectively,
regardless of whether the treatments were conducted in the presence of cell culture medium or human serum.
Conclusions: The results provide quantitative evidence for the potential use of a variety of approaches for
inactivating HCV. The ability of HCVcc to survive ambient temperatures warrants precautions in handling and
disposing of objects and materials that may have been contaminated with HCV.
Background
Hepatitis C virus (HCV) is a small enveloped, positive-
stranded RNA virus classified within the family Flavivir-
idae,g e n u sHepacivirus. HCV affects an estimated 170
million people worldwide and is a global health pro-
blem. Unlike most RNA viruses which usually cause
acute diseases, HCV establishes life-long, persistent,
intrahepatic infections in a majority of infected indivi-
duals, leading frequently to the development of cirrhosis
and hepatocellular carcinoma [1,2]. Because the current,
interferon-based treatment regimens eradicate HCV in
only about 50% of patients, prevention of HCV infection
is pivotal for controlling this viral pathogen.
HCV is transmitted primarily via percutaneous expo-
sure to infectious blood. Prior to the introduction of
anti-HCV screening tests in the early 1990s, receiving
blood and blood products or organ transplants was a
major risk factor for acquiring HCV infection. Currently,
injection of illicit drugs represents a major risk, while
other routes of infection, including occupational expo-
sure (such as needle stick), sex, and mother-to-infant
transmission (with the exception of HIV-coinfected
mother), seem infrequent [3]. Interestingly, it was shown
recently in the chimpanzee model that HCV in infec-
tious plasma could survive drying and environmental
exposure to room temperature for at least 16 h. This
finding has raised the possibility of person-to-person
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and medical devices [4]. Clearly, it is fundamental to
quantitatively determine the stability of HCV under
environmental conditions and evaluate reliable proce-
dures for inactivating this virus. However, such efforts
have been hampered by the lack of an efficient cell cul-
ture system and convenient, small animal models for
HCV. Although HCV RNA and antigens have been used
as indicators for the presence or absence of virus parti-
cles, such detection methods do not distinguish between
the infectious and inactivated viruses [4-6]. To circum-
vent this, several related viruses in the family Flaviviri-
dae that can be readily cultured in vitro, e.g., bovine
viral diarrhoea virus (BVDV, genus Pestivirus), have
been used as surrogates for HCV to study the inactiva-
tion process [7,8]. Although these model viruses show
similarity in virion and genome structure to HCV, more
relevant systems are still needed to assess the reliable
procedures for inactivating HCV.
The recent establishment of an HCV cell culture sys-
tem based on a particular molecular clone, JFH-1, offers
the opportunity of evaluating the inactivation methods
for HCV directly [9-12]. Using the Huh7-25-CD81 cell
line that is highly susceptible to HCVcc infection [13],
the stability of HCVcc (JFH-1 strain) at different envir-
onmental temperatures (37°C, room temperature, and 4°
C) was assessed in this study. In addition, the efficacy of
several commonly used viral inactivation methods,
including heat treatment, UVC light irradiation, alde-
hyde-mediated fixation, and detergent treatments in
eliminating HCVcc infectivity were evaluated. The
results revealed that all of these methods were able to
inactivate HCVcc, provided proper conditions are met.
Results
Stability of HCVcc at 37°C, RT, and 4°C
To investigate the ability of HCVcc to survive different
environmental temperatures, the spontaneous reductions
of viral titer at 37°C, RT (25 ± 2°C), and 4°C were deter-
mined individually. The HCVcc stock (2.5 × 10
4 FFU/ml
in culture medium) lost its infectivity after incubation at
37°C for 48 h, when the FFU assay became negative and
no residual infectivity was found upon three successive
passages of the inoculated Huh7-25-CD81 cultures (Fig-
ure 1A). Most of the infectivity loss occurred within the
first 24 h [from 2.5 × 10
4 FFU/ml to (5.7 ± 0.6) × 10
1
FFU/ml, a 2.6-log reduction], while a further 0.4-log
reduction in the following 16 h brought the virus titer
down to (2.3 ± 0.6) × 10
1 FFU/ml, close to the detection
limit (10 FFU/ml). In contrast to 37°C, viral titers
declined much more slowly and smoothly at RT (Figure
1B). Incubation for every 2 days led to 0.4- to 0.5-log
reduction in viral titers until day 14 when infectivity
dropped to the level of detection limit. The virus stock
became completely devoid of infectivity at day 16 (Fig-
ure 1B) and later (data not shown). When incubated at
4°C, no obvious loss of viral infectivity was detected
within the first 4 weeks (Figure 1C). However, we
noticed a nearly 0.5-log reduction of viral titer after 6
weeks, when the experiments were ended. Lindenbach
et al reported that the infectivity of J6/JFH1 HCVcc did
not change after three freeze-thaw cycles [10]. Consis-
tent with this, we found no obvious reduction of infec-
tivity even after five cycles of freezing and thawing of
the JFH1 HCVcc stock (data not shown). This suggests
that HCVcc is relatively insensitive to freeze-thaw
manipulation.
To determine whether the presence of human blood
affects the stability of HCVcc, a concentrated HCVcc
stock was diluted in normal human serum to achieve a
titer of 1.0 × 10
5 FFU/ml. At RT, this HCVcc-containing
serum was found to gradually loose its infectivity in 3
weeks, with 1.4- to 1.7- log reduction in viral titer after
every week of incubation (Figure 1D). However, when
the HCVcc diluted in human serum (1.0 × 10
5 FFU/ml)
was dried on the surface of cell culture dishes and incu-
bated at RT for 1 week, no infectivity was detected
upon inoculation of the reconstituted serum onto naïve
Huh7-25-CD81 cells even after three consecutive cell
passages (data not shown). In aggregate, these results
suggest that HCVcc is able to survive ambient condi-
tions especially in a liquid environment, and that stabi-
lity of HCVcc is inversely correlated with temperature.
Effect of heat treatment on HCVcc infectivity
To evaluate the sensitivity of HCVcc to heat treatment,
aliquots of HCVcc stock (2.5 × 10
4 FFU/ml) were trea-
ted with three increasing temperatures (56°C, 60°C, and
65°C, respectively). As shown in Figure 2A, at 56°C
HCVcc lost most of its infectivity within 30 min, with a
2.9-log reduction in viral titer [from 2.5 × 10
4 FFU/ml
to (3.3 ± 0.6) × 10
1 FFU/ml). However, after 35 min, a
very small amount of infectious virus was still detectable
[(1.3 ± 0.6) × 10
1 FFU/ml]. Complete viral inactivation
took place at 40 min (Figure 2A), and no residual infec-
tivity was detected for samples treated beyond this time
point (data not shown). Heat treatments at higher tem-
peratures led to a more rapid decline in viral titer. At
60°C or 65°C (Figure 2B), HCV stocks were inactivated
completely by 8 or 4 min, respectively.
Similar kinetics of viral inactivation was observed
when heat treatment was performed on HCVcc stocks
spiked in human serum. When incubated at 56°C, the
viral titer dropped by 3.6-log in the first 30 min [from
1.0 × 10
5 FFU/ml to (3.3 ± 0.6) × 10
1 FFU/ml]. By 40
min viral infectivity could be no longer detected (Figure
1C). At 60°C and 65°C, the HCVcc-containing serum
was completely inactivated by 10 and 4 min, respectively
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HCVcc is sensitive to heat treatment and 56°C or higher
temperatures could be used for effective HCVcc inacti-
vation. Of note, the presence of human serum does not
seem to affect the susceptibility of HCVcc to heat
treatment.
Effect of UVC light irradiation on HCVcc infectivity
To examine the effect of continuous UVC light on
HCVcc infectivity, 200-μl aliquots of HCVcc stock
(2.5 × 10
4 FFU/ml) were placed in 48-well plates and
subjected to UVC light irradiation for different time
points, and the residual titers were determined immedi-
ately. As shown in Figure 3A, viral titers declined
rapidly following UVC irradiation, by 1.4- and 2.4-log,
in the first 15 and 30 sec of exposure, respectively. After
45 sec, the viral titer decreased to a level [(2.7 ± 1.2) ×
10
1 FFU/ml] close to the detection limit of the FFU
assay. HCVcc infectivity was eliminated completely after
1 min of irradiation. In contrast, the control, nonirra-
diated samples incubated at RT for 1 min showed no
loss in titer (data not shown).
The effect of UVC light on the infectivity of HCVcc
spiked in human serum was also investigated. As shown
in Figure 3B, an 1.6-log decrease in viral infectivity was
observed after the first 30 sec of irradiation [from 1.0 ×
10
5 FFU/ml to (2.6 ± 0.5) × 10
3 FFU/ml)]. Exposure to
UVC light for 90 sec brought the viral titer down to a
level that was close to the limit of detection, while an
additional 30-sec exposure (a total of120 sec) completely
eliminated the residual infectivity (Figure 3B). Given that
the radiant intensity at a distance of 30 cm from the
UVC lamp was 450 μW/cm
2 (where μW=1 0
-6 J/sec),
these data suggest that continuous UVC light at a
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Figure 1 Stability of HCVcc at 37°C, room temperature (25 ± 2°C), and 4°C. Aliquots (300 μl) of an HCVcc stock with an initial infectious
titer of 2.5 × 10
4 FFU/ml were incubated at 37°C (A), room temperature (B), or 4°C (C). In (B) the decay rate of HCVcc infectivity at room
temperature was calculated as 0.254-log/day, after the data were fit to a linear regression model (R
2 = 0.9963). (D). Aliquots of HCVcc diluted in
normal human serum (1.0 × 10
5 FFU/ml) were incubated at room temperature. At indicated time points, viral titers were determined by FFU
assay on Huh7-25-CD81 cells and shown as mean log10 FFU/ml ± SD. The dashed line indicates the detection limit of the FFU assay (10 FFU/ml).
The asterisks in (A), (B) and (D) denote time points when infectivity was completely lost (tested negative for HCV NS3 expression to the third cell
passage).
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Page 3 of 12radiation dose of 5.4 × 10
-2 J/cm
2 (t = 120 sec) is sufficient
to inactivate HCVcc with a titer of 1.0 × 10
5 FFU/ml.
Effects of formaldehyde and glutaraldehyde treatments
on HCVcc infectivity
MTT assay was first carried out to determine the alde-
hyde concentrations at which they no longer affected
cell viability. It was found that 0.00037% formaldehyde
and 0.0001% glutaraldehyde no longer had a demon-
strable effect on cell growth/viability (Figure 4A). Also,
at these aldehyde concentrations, the viral titration
results were not perturbed (Table 1 and 2). Therefore,
viral samples treated with 0.037% formaldehyde or
0.01% glutaraldehyde were diluted 100-fold for infectiv-
ity assay. The reduction in viral titer of an HCVcc stock
(4.1 × 10
4 FFU/ml) following exposure to each of the
aldehydes is summarized in Table 1. At 2 h posttreat-
ment of formaldehyde, a single fluorescent focus was
detected in one of the triplicate wells in the FFU assay,
while the other two wells showed negative results. Virus
samples treated for 2.5 h were negative in the FFU
assay; however, a positive IFA result was observed at the
second cell passage, indicating the presence of residual
infectious virus. After 3 h of treatment, no residual
infectivity could be detected up to the third cell passage
(Table 1). Compared with 0.037% formaldehyde, 0.01%
glutaraldehyde exhibited a higher efficacy in viral inacti-
vation. Ten minutes of glutaraldehyde treatment
resulted in more than 1-log reduction in infectivity.
After 20 min, the virus stock was inactivated completely,
with no residual infectivity being detected up to the
third cell passage (Table 1).
The effect of aldehydes on the infectivity of HCVcc in
human serum (1.0 × 10
5 FFU/ml) was also evaluated by
using the same procedure as described above. As shown
in Table 2, 3 hours of incubation in 0.037% formalde-
hyde decreased the viral titer to the limit of detection
[(1.0 ± 0.0) × 10
3 FFU/ml, a 2-log drop]. After 4 hours,
no residual infectivity could be detected (Table 2). In
agreement with the results for HCVcc in culture med-
ium, 0.01% glutaraldehyde was also more effective than
0.037% formaldehyde in inactivation of HCVcc in
human serum. The results of FFU assay became negative
after treatment with 0.01% glutaraldehyde for 30 min,
although a small amount of infectious virus was detect-
able at the second cell passage, By 40 min, no residual
infectivity could be detected up to the third cell passage,
indicating that effective viral inactivation was achieved
(Table 2). In all experiments, the control, PBS-treated
samples showed no obvious loss of infectivity when
titrated in the presence of 0.00037% formaldehyde or
0.0001% glutaraldehyde (data not shown). These results
suggest that both of the aldehydes are able to inactivate
HCVcc, regardless of the presence of human serum in
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Figure 2 Inactivation of HCVcc by heat treatment. Aliquots (100
μl) of an HCVcc virus stock (2.5 × 10
4 FFU/ml) or HCVcc diluted in
normal human serum (1.0 × 10
5 FFU/ml) were incubated in water
baths at 56°C (A and C), 60°C and 65°C (B and D). At indicated time
points post incubation, samples were removed, cooled on ice-water
bath, and their residual infectivity titrated on Huh7-25-CD81 cells.
The dashed line indicates the detection limit of the FFU assay (10
FFU/ml). The asterisks denote time points when infectivity was
eliminated completely (tested negative in FFU assay and remained
negative for HCV NS3 expression to the third cell passage). The
decay rate of HCVcc infectivity at 56°C was calculated as 0.089-log/
min and 0.119-log/min, for HCVcc in culture medium (A) and
human serum (C), respectively, after the data were fit to a linear
regression model (R
2 = 0.9883 and 0.9813, respectively).
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than is formaldehyde.
Effects of detergent treatments on HCVcc infectivity
To determine the detergent concentrations at which
they were no longer cytotoxic to cells, Huh7-25-CD81
cells were treated with individual, serially diluted deter-
gents and subjected to MTT assay to assess cell viability.
Based on the MTT assay results (Figure 4B and 4C),
HCVcc stocks (4.1 × 10
4 FFU/ml) or those spiked in
human serum (1.0 × 10
5 FFU/ml) were treated with
0.1% SDS, 0.2% Triton X-100, or 0.2% NP-40, and then
tested for infectivity at either 100-fold (SDS-treated
samples) or 400-fold (Triton X-100- or NP-40-treated
samples) dilution. As summarized in Table 3, all of the
detergent-treated samples were negative in the FFU
assay and demonstrated no residual infectivity upon
three consecutive passages of the inoculated cells
(Table 3). In contrast, control samples not treated with
detergents showed no obvious loss in virus titers.
The effect of detergents on disrupting intracellular
HCVcc virions was also evaluated. JFH-1-infected
Huh7-25-CD81 cultures (with 100% cells positive for
NS3 as determined by immunofluorescence assay) were
lysed in each of the detergent solutions (0.1% SDS, 0.2%
Triton X-100, or 0.2% NP-40 in PBS, respectively), and
the clarified supernatants were tested for infectivity on
naïve Huh7-25-CD81 cells at 100-fold (SDS-lysed sam-
ples) or 400-fold (Triton X-100- or NP-40-lysed sam-
ples) dilution, respectively. No infectivity was detected
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Figure 3 Inactivation of the HCVcc by UVC light irradiation. Aliquots (200 μl) of an HCVcc stock (A) or normal human serum containing
HCVcc (B) were placed 30 cm beneath the longitudinal midpoint of a UVC lamp. Samples were removed at indicated time points, and viral
titers were determined on Huh7-25-CD81 cells immediately. The dashed line indicates the detection limit of the FFU assay (10 FFU/ml). The
asterisk denotes the time point when infectivity was completely lost (tested negative in FFU assay and remained negative for HCV NS3
expression to the third cell passage). The decay rate of HCVcc infectivity after UVC light irradiation was calculated as 0.067-log/sec and 0.041-log/
sec, for HCVcc in culture medium (A) and human serum (B), respectively, after the data were fit to a linear regression model (R
2 = 0.9738 and
0.9891, respectively).
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Figure 4 MTT assay of cytotoxicity associated with various concentrations of aldehydes or detergents. Solutions of formaldehyde (37%
or glutaraldehyde (50%) (A), SDS (0.1%) (B), and Triton X-100 (0.2%) or NP-40 (0.2%) (C) were diluted serially in cell culture medium by dilution
factors indicated in the X-axes, then added to Huh7-25-CD81 cells seeded in 96-well plates. The treated cells were refed with 100 μl of fresh
medium after 6 h of incubation. MTT assay was carried out after an additional 72 h as described in Methods. Data are presented as the
percentage of cell viability relative to the untreated controls (mean ± SD, n = 3).
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sages of inoculated cells (Table 3), while the control cell
lysate prepared by freezing and thawing in the absence
of any detergents retained high infectivity (Table 3).
Taken collectively, these results suggest that each of the
detergents, at the tested concentration, is highly effective
in eliminating the infectivity of both extracellular and
intracellular HCVcc particles.
Discussion
In this study, a detailed analysis was conducted on the
stability of HCVcc at various environmental tempera-
tures. Also evaluated was the efficacy of several conven-
tional viral inactivation procedures in eliminating
HCVcc infectivity.
It has been shown previously that genotype 1a HCV in
infectious plasma could survive drying and environmen-
tal exposure to RT for at least 16 h [4]. The results of
t h ec u r r e n ts t u d yh a v ed e m o n s t r a t e dt h a tJ F H - 1v i r u s
(genotype 2a) grown in cell culture can survive 37°C
and RT for 2 and 16 days, respectively (Figure 1A and
1B). Of note, the stability of JFH1 HCVcc spiked in
human serum did not differ much from those in cell
culture medium when incubated at RT (Fig. 1D). When
stored at 4°C, JFH-1 virus was found to be relatively
stable, without drastic losso ft i t e rd u r i n gt h e6 - w e e k
observation period (Figure 1C). The latter result is in
agreement with a previous report dealing with the J6/
JFH1 chimeric virus [10]. The ability of HCVcc to sur-
vive various environmental temperatures warrants pre-
cautions in handling and disposing objects and materials
that may have been contaminated with HCV, to mini-
mize the risk of HCV transmission.
Heat treatment is a widely used viral inactivation
method that is effective against both enveloped and
nonenveloped viruses [14]. The mechanisms of heat-
mediated inactivation include denaturation of viral pro-
teins, as well as disassembly of virus particles into non-
infectious viral subunits and single proteins [15]. Viruses
other than HCV in the family Flaviviridae have been
shown to be sensitive to heat treatment. Yellow fever
virus is routinely inactivated at 56°C for 30 min. At 60°
C, BVDV and yellow fever virus have been reported to
be inactivated effectively in 30 and 5 min, respectively
[8,16]. In the current study, similar kinetics of viral inac-
tivation following heat treatment was observed for both
the HCVcc in culture medium and those in human
serum. While 10 min at 60°C or 4 min at 65°C was suf-
ficient to eliminate the infectivity of HCVcc, incubation
for 40 min was required to achieve complete viral inacti-
vation at 56°C (Figure 2). Therefore, pretreatment of
HCV positive sera for 30 min at 56°C may not be abso-
lutely reliable in eliminating their infectivity. However,
because the efficiency of heat treatment could be
affected by a variety of factors, such as the initial viral
titer, protein concentration in virus suspension, as well
as the existence of viral aggregates [8,17] the exact tem-
perature and time required for reliable HCV inactivation
should be evaluated under each specific condition.
UV light irradiation is another commonly used physi-
cal method for viral inactivation. UVC with a wave-
length range of 200-280 nm prevents viral replication by
inducing formation of pyrimidine dimers in the viral
Table 1 Effects of formaldehyde and glutaraldehyde on
infectivity of HCVcc in culture medium
Treatment Infectious titer
(FFU/ml)
IFA result
2
nd cell passage 3
rd cell passage
Formaldehyde (0.037%)
0 h (3.9 ± 0.3) × 10
4a NT
c NT
0.5 h (1.1 ± 0.1) × 10
4 NT NT
1.0 h (4.0 ± 1.0) × 10
3 NT NT
1.5 h (1.7 ± 0.6) × 10
3 NT NT
2.0 h ≤ 1.0 × 10
3b positive NT
2.5 h < 1.0 × 10
3 positive NT
3.0 h < 1.0 × 10
3 negative negative
Glutaraldehyde (0.01%)
0 min (4.0 ± 0.3) × 10
4a NT NT
10 min (3.3 ± 0.6) × 10
3 NT NT
20 min < 1.0 × 10
3 negative negative
a Untreated viral samples were retitrated in culture medium containing
0.00037% formaldehyde or 0.0001% glutaraldehyde as controls.
bOne focus was detected in one of the triplicate wells in FFU assay.
c NT, not tested. Samples with positive results in FFU assay or at the second
cell passage were not tested for NS3 staining for the third cell passage.
Table 2 Effects of formaldehyde and glutaraldehyde on
infectivity of HCVcc in human serum
Treatment Infectious titer
(FFU/ml)
IFA result
2
nd cell passage 3
rd cell passage
Formaldehyde (0.037%)
0 h (8.5 ± 0.7) × 10
4a NT
b NT
1.0 h (1.9 ± 0.4) × 10
4 NT NT
2.0 h (3.5 ± 0.7) × 10
3 NT NT
3.0 h (1.0 ± 0.0) × 10
3 NT NT
4.0 h < 1.0 × 10
3 negative negative
Glutaraldehyde (0.01%)
0 min (9.5 ± 0.7) × 10
4a NT NT
10 min (1.8 ± 0.2) × 10
4 NT NT
20 min (2.5 ± 0.7) × 10
3 NT NT
30 min < 1.0 × 10
3 Positive NT
40 min < 1.0 × 10
3 negative negative
a Untreated viral samples were retitrated in culture medium containing
0.00037% formaldehyde or 0.0001% glutaraldehyde as controls.
b NT, not tested. Samples with positive results in FFU assay or at the second
cell passage were not tested for NS3 staining for the third cell passage.
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suspended in PBS, could be inactivated completely by
1.6 J/cm
2 UVC light, while viral suspension containing
5% FBS required a higher radiation dose [7]. The cur-
rent study demonstrated that HCVcc in culture medium
(2.5 × 10
4 FFU/ml, volume depth of 0.2 cm) could be
inactivated completely by UVC irradiation at a dose of
2.7 × 10
-2 J/cm
2 within 1 min (Figure 3A), while those
spiked in human serum (1.0 × 10
5 FFU/ml) required an
irradiation dose of 5.4 × 10
-2 J/cm
2 for full inactivation
(Figure 3B). Therefore, UVC light irradiation represents
a highly effective means for inactivating HCVcc, the effi-
ciency of which is not affected by human serum compo-
nents that may interact with HCV virons in vivo.
However, the irradiation dose required for each specific
occasion may depend on the sample volume and its
initial viral titer.
As a chemical cross-linking reagent, formaldehyde
inactivates viruses primarily by denaturing viral proteins,
as well as the nucleic acids [19,20]. Because the immu-
nogenicity of the viral particles can be retained during
inactivation, formalin (37% formaldehyde) treatment is
the most used technique for preparing inactivated virus
vaccines. For tissue fixation for histology or immunohis-
tochemistry, 10% formalin (or 4% paraformaldehyde) is
routinely used. Glutaraldehyde is another effective pro-
tein cross-linking reagent, mostly used for fixation of
tissues for electron microscopy. Although the detailed
mechanisms are not entirely clear yet, successful inacti-
vation of many viruses with glutaraldehyde, including
hepatitis B virus, human immunodeficiency virus (HIV),
and SARS coronavirus, has been reported [18,21,22].
We demonstrated here that at RT, 3 h of exposure to
formaldehyde (0.037%) or 20 min of exposure to glutar-
aldehyde (0.01%), respectively, could reduce HCVcc
infectivity from 4.1 × 10
4 FFU/ml to undetectable levels
(Table 1). At these concentrations both aldehydes were
also effective in inactivating HCVcc in the presence of
human serum (Table 2). The slightly longer times
required (4 h for formaldehyde treated samples and 40
min for glutaraldehyde treated samples, respectively)
were most likely attributed to the 2.5-fold higher initial
titer of the HCVcc stock tested (1.0 × 10
5 FFU/ml).
However, a limitation of the current study is that,
because of the cytotoxic effect of the aldehydes, the
infectivity of viral samples could be analyzed at only the
100-fold dilution, which may somehow have reduced
the sensitivity of the assay. It should be noted, however,
the routinely used concentrations of aldehydes for fixa-
tion purposes (4% for formaldehyde and 2.5% for glutar-
aldehyde) are far in excess of the ones examined in the
current study and, therefore, should be highly efficient
in achieving HCV inactivation.
Detergents are highly efficient at disrupting the lipid-
enveloped viruses, and solvent/detergent (S/D) treat-
ment is a standard method for inactivating viruses pre-
sent in human blood products [22]. The effects of both
ionic (SDS) and nonionic (Triton X-100 and NP-40)
detergents on HCVcc infectivity have been investigated
here. All three detergents at the tested concentrations
reduced HCVcc infectivity rapidly to undetectable levels
(Table 3). Importantly, both intracellular HCVcc and
those released into culture fluid could be inactivated by
each of these detergents, regardless of the presence of
human serum, indicating that components of culture
medium, human serum or intracellular proteins did not
interfere with the disruptive processes exerted by these
detergents. Under current experimental conditions,
effective HCVcc inactivation took place immediately
after vortex-mixing, rendering it impossible to delineate
the kinetics of viral infectivity reduction during the
detergent treatment process. This finding is reminiscent
Table 3 Effects of detergent treatments on HCVcc infectivity
Treatment Infectious titers before treatment (FFU/ml)
a FFU assay after treatment IFA result at the 3
rd cell passage
0.1% SDS
HCVcc in culture medium (4.1 ± 0.2) × 10
4 negative negative
HCVcc in human serum (9.5 ± 0.7) × 10
4 negative negative
cell lysates (5.5 ± 0.1) × 10
5 negative negative
0.2% Triton X-100
HCVcc in culture medium (2.0 ± 0.2) × 10
4 negative negative
HCVcc in human serum (6.0 ± 0.0) × 10
4 negative negative
cell lysate (3.1 ± 0.2) × 10
5 negative negative
0.2% NP-40
HCVcc in culture medium (1.6 ± 0.2) × 10
4 negative negative
HCVcc in human serum (5.5 ± 0.2) × 10
4 negative negative
cell lysate (2.9 ± 0.2) × 10
5 negative negative
a Untreated viral samples or intracellular viral infectivity in untreated, HCVcc-infected cell lysates prepared by freeze-and-thaw were retitrated in the presence of
0.001% SDS, 0.0005% Triton X-100 or 0.0005% NP-40, respectively, to keep in line with the final concentration of the detergents in the treated samples during
titration.
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demonstrated that HIV-1 spiked in solution containing
1% Triton X-100 was inactivated completely within 1
min [23]. As in the case of the aldehyde-inactivation
experiments, the cytotoxic effect of detergents limited
the sensitivity of the current assays. Interestingly,
although 0.0005% Triton X-100 and 0.0005% NP-40 had
no detectable effect on cell viability (Figure 4C), they
still lowered HCVcc infectivity by 1.7- to 2.5-fold when
the latter was compared with those determined in the
presence of 0.001% SDS or without any detergent (Table
3). Most likely, the residual Triton X-100 or NP-40 still
had some disruptive effect on virion integrity, which is
important for viral infectivity. Alternatively, these deter-
gents may have caused some cell surface alterations at
this extremely low concentration that affect the process
of HCVcc entry. However, to maintain the sensitivity of
the assay, the detergent-treated samples were not
diluted further for the infectivity test. Collectively, the
robustness and immediate action of detergents in
destroying HCVcc infectivity support the use of S/D
treatment procedures in eliminating potential HCV con-
taminations in blood products.
Conclusions
In summary, results presented in the current study
revealed the stability of HCVcc (genotype 2a, JFH-1
strain) under different temperatures and provided quanti-
tative evidence that heat, UVC light irradiation, aldehyde
(formaldehyde and glutaraldehyde), and detergent treat-
ments all can be used as effective means for inactivating
HCVcc. However, because the stability and resistance of
HCV to different inactivation methods may vary from
genotype to genotype, and even strain to strain, the opti-
mal method and procedure used for HCV inactivation
should be verified under each particular circumstance.
We also note that the results of the current study were
developed using an in vitro cell culture system based on
hepatoma Huh7 cells, which may differ from normal
human hepatocytes in supporting HCV infection. Thus,
to what extent the procedures described herein can be
applied to an in vivo setting awaits further evaluation.
Methods
Cell culture and virus stocks
The Huh7-25-CD81 cell line (a generous gift from Dr.
Takaji Wakita), a Huh7 cell clone that stably expresses
human CD81 [13], was used throughout the experi-
ments. This cell line was chosen because we found it
was approximately 1.5- to 2-fold more sensitive for titra-
tion of HCVcc infectivity than was the Huh7.5.1 cell line
(data not shown). Cells were maintained in DMEM sup-
plemented with 10% fetal bovine serum (Invitrogen), 10
mM HEPES (Invitrogen), and 400 μg/ml G418 (Merck,
Germany) at 37°C in 5% CO2. To generate JFH-1 virus
stocks, cell culture supernatant collected from full-
length JFH-1 RNA-transfected Huh7 cells (kindly pro-
vided by Dr. Takaji Wakita) was used to infect Huh7-
25-CD81 cells grown in T25 flasks at a multiplicity of
infection (MOI) of 0.01. The infected cells were pas-
saged at 3-day intervals with 1:3 to 1:4 split ratios into
progressively larger culture vessels. At 12 days postinfec-
tion, the culture supernatants were harvested, clarified
by centrifugation (5 min at 4000 rpm), and stored in ali-
quots at -70°C as the HCVcc stock. The infectious titer
of the virus stock was determined by focus-forming unit
(FFU) assay as described immediately below (the infec-
tious titers of the un-concentrated virus stocks used
were either 2.5 × 10
4 FFU/ml or 4.1 × 10
4 FFU/ml in
the current study, as specified in each experiment).
To determine the stability of HCVcc and its suscept-
ibility to individual inactivation methods in the presence
of human serum, a condition which better mimics circu-
lating HCV virions in vivo, HCVcc stock was first con-
centrated using the Amicon Ultra-15 device (100,000
NMWL membrane; Millipore) as described previously
[11]. The concentrated virus stock (1.1 × 10
6 FFU/ml)
was then diluted 11-fold in normal human serum that
had been heat-inactivated to achieve an infectious titer
of 1.0 × 10
5 FFU/ml. This human serum containing
HCVcc was stored at -70°C in aliquots until use.
HCV infectivity assay
The infectious titers of virus stocks and treated viral
samples were determined by FFU assay, as described
previously [24], using an indirect immunofluorescence
assay (IFA) for HCV NS3. In brief, 100 μlo f1 0 - f o l d
serially diluted samples (the dilution factors generally
ranged from 1:1 to1:1000) were inoculated onto naïve
Huh7-25-CD81 cells seeded in 96-well plates 1 day
before infection (7000 cells/well). After 6 h of incuba-
tion at 37°C, cells were refed with 100 μl fresh medium.
Following an additional 72 h, cells were fixed in 4% par-
aformaldehyde for 30 min at room temperature (RT),
blocked for 60 min in a blocking buffer (3% BSA, 0.3%
Triton X-100, 10% FBS in PBS), followed by incubation
with a polyclonal antibody against HCV NS3 (kindly
provided by Dr. Takaji Wakita) at 1:500 dilution. After 2
h incubation at RT, cells were washed extensively with
PBS and then incubated with an FITC-conjugated goat
anti-rabbit IgG (Beijing Zhongshanjinqiao, China) at
1:100 dilution for 1 h. Following PBS washes, the num-
bers of fluorescent foci (a focus is defined as a cluster of
infected cells immunostained positive for NS3 antigen)
per well at appropriate dilutions (generally containing 5
to 100 foci per well) were counted. The infectious titers,
expressed as FFU/ml, were calculated from the average
foci number of triplicate or duplicate (for samples
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The detection limit of the FFU assay was 10 FFU/ml.
For samples with infectious titers below the detection
limit of the assay, the potential residual infectivity was
examined as follows. Naïve Huh7-25-CD81 cells seeded
in 96-well plates were inoculated with samples to be
tested (100 μl/well). Inoculated cells were passaged at 3-
day intervals from one well into three wells at each pas-
sage (with a 1:3 split ratio) to allow growth of residual
infectious virus. IFA for NS3 were performed on each
cell passage. If the IFA results remained negative for
three successive cell passages (up to 9 days postinocula-
tion), the tested sample was considered to be inactivated
completely.
Viral stability assays
An HCVcc stock with a titer of 2.5 × 10
4 FFU/ml was
dispensed into 300-μl aliquots in tightly capped, 1.5-ml
microcentrifuge tubes and then incubated at 37°C, RT
(25 ± 2°C), and 4°C, respectively, and protected from
light. Aliquots incubated at 37°C were removed every 8
h, while those incubated at RT or 4°C were removed
every 2 days or every 2 weeks, respectively, and stored
at -70°C until virus titration on Huh7-25-CD81 cells.
For viral stability assays for HCVcc spiked in normal
human serum (1.0 × 10
5 FFU/ml), aliquots were incu-
bated at RT and removed every 7 days for titration.
All the time points selected in the experiments
were designed based on the results of several pilot
experiments.
Heat treatment
An HCVcc stock in culture medium (2.5 × 10
4 FFU/ml)
or concentrated HCVcc stock diluted in human serum
(1.0 × 10
5 FFU/ml) was dispensed into 100-μl aliquots
in tightly capped, 1.5-ml microcentrifuge tubes and then
incubated in water baths with temperatures of 56°C, 60°
C, and 65°C, respectively. At designated time points, ali-
quots were removed, transferred immediately into ice-
water bath to stop the effect of heat, and then subjected
to FFU assay for virus titration.
UVC light irradiation
Two hundred-microliter aliquots of an HCVcc stock
(2.5 × 10
4 FFU/ml) or HCVcc diluted in normal human
serum (1.0 × 10
5 FFU/ml) were placed in 48-well plates
to give a volume depth of about 0.2 cm and then
exposed to continuous UVC light 30 cm beneath the
longitudinal midpoint of a UVC lamp (model: ZSZ20D,
wavelength = 253.7 nm, Beijing Haidian Konghou High
Temperature Composite Material Factory, China). At
the distance of 30 cm, the radiant intensity of the UVC
lamp was 450 μW/cm
2 (where μW=1 0
-6 J/sec), as spe-
cified by the manufacturer. After varying lengths of
exposure, samples (200 μl) were removed, and their resi-
dual infectivity was titrated on Huh7-25-CD81 cells
immediately. Control samples were set up in parallel
and incubated for the same time period but protected
from UVC light.
MTT cytotoxicity assay
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetra-
zolium bromide] cytotoxicity assay was carried out to
determine the concentrations of aldehydes or detergents
at which they were no longer cytotoxic to Huh7-25-
CD81 cell. Solutions of aldehydes (37% formaldehyde
and 50% glutaraldehyde) or detergents [sodium dodecyl
sulfate (SDS, 0.1%), Triton X-100 (0.2%) or nonidet P-40
(NP-40, 0.2%)] were diluted serially in cell culture med-
ium, respectively (the range of concentrations for each
reagent was designed based on the results of pilot
experiments). The diluted reagents were then added to
Huh7-25-CD81 cells seeded in 96-well plates (7000
cells/well) 1 day before. After 6 h of incubation at 37°C,
the treated cells were refed with 100 μlo ff r e s hc u l t u r e
medium to keep the exposure time to the individual
reagents the same as that in HCV infectivity assay. Fol-
lowing an additional 72 h, 20 μl of MTT solution (5
mg/ml, Sigma-Aldrich) was added to each well. After a
4-h incubation at 37°C, the MTT solution was removed
and replaced with 200 μl of dimethyl sulfoxide (DMSO,
Sigma-Aldrich) per well. After the formazan crystals
were dissolved by agitation (10 min at RT), the absor-
bance of solution in each well was measured at 490 nm
using an enzyme-linked immunosorbent assay plate
reader (Bio-Rad). The percentage of cell viability was
calculated as the ratio of absorbance in treated cells
compared with that in untreated controls. All experi-
ments were performed in triplicate and repeated twice.
Formaldehyde and glutaraldehyde treatments
Formaldehyde (37%) or glutaraldehyde (50%) solutions
(Beijing Chemical Reagents Company, China) were
diluted in PBS at 1:10 (formaldehyde) or 1:50 (glutaral-
dehyde), respectively, then added to 500-μl viral samples
[HCVcc stock in cell culture medium (4.1 × 10
4 FFU/
ml) or HCVcc-containing human serum (1.0 × 10
5 FFU/
ml)] to achieve a final concentration of 0.037% (formal-
dehyde) or 0.01% (glutaraldehyde), respectively. After
different time periods at RT, treated samples were
diluted 100-fold in culture medium immediately to stop
the inactivation reaction, as well as to eliminate the
cytotoxic effect of aldehydes in subsequent FFU assays
(according to the results of the MTT assay, the presence
of 0.00037% formaldehyde or 0.0001% glutaraldehyde had
no appreciable effect on the viability of Huh7-25-CD81
cells). Immediately after the dilution, HCV infectivity in
samples was titrated by FFU assay in Huh7-25-CD81
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subjected to the residual infectivity test, as described in
“HCV infectivity assay” As control, PBS was substituted
for the aldehydes to treat the virus stocks, which were
then diluted 100-fold to infect cells in the presence of
either 0.00037% formaldehyde or 0.0001% glutaraldehyde,
respectively.
Detergent treatments
Solutions of 0.5% SDS (w/v), 1% Triton X-100 (v/v), or
1% NP-40 (v/v) (all prepared in PBS) were added to
500-μl aliquots of viral samples [HCVcc stock in cell
culture medium (4.1 × 10
4 FFU/ml) or normal human
serum containing HCVcc (1.0 × 10
5 FFU/ml)] to achieve
a final concentration of either 0.1% (SDS) or 0.2% (Tri-
ton X-100 and NP-40). After a gentle mixing (within 1
min), treated samples were diluted 100-fold (SDS-trea-
ted samples) or 400-fold (Triton X-100- or NP-40-trea-
ted samples) immediately in culture medium to negate
the cytotoxic effect of detergents (based on the MTT
assay results, the presence of 0.001% SDS, 0.0005% Tri-
ton X-100, or 0.0005% NP-40 had no demonstrable
effect on the viability of Huh7-25-CD81 cells), then sub-
jected to FFU assay. Samples with negative FFU assay
results were examined for residual infectivity. As con-
trol, PBS was used in place of the detergents to treat the
virus stocks, which were subsequently diluted either
100- or 400-fold to infect the Huh7-25-CD81 cells in
the presence of 0.001% SDS, 0.0005% Triton X-100, or
0.0005% NP-40, respectively.
To assess the ability of detergents to disrupt intracel-
lular HCV, JFH-1 infected Huh7-25-CD81 cell mono-
layers grown in 24-well plates (approximately 100% of
cells stained positive for NS3 at the time of cell lysis as
examined by IFA) were detached by trypsin/EDTA and
washed extensively with PBS, and cell pellets were resus-
pended in 50 μl PBS containing 0.1% SDS, or 0.2% Tri-
ton X-100, or 0.2% NP-40, respectively (each detergent
was disruptive to cells at these concentrations as visua-
lized by microscopy). After centrifugation, the superna-
tants of cell lysates were diluted 100-fold (SDS-lysed
samples) or 400-fold (Triton X-100- or NP-40-lysed
samples) in culture medium for infectivity assays. IFA of
HCV NS3 was performed on inoculated cells for three
consecutive cell passages. As control, infected cells
washed extensively with PBS were pelleted and resus-
pended in 50 μl PBS and lysed by three cycles of freez-
ing and thawing (-70°C to 37°C), and the infectivity of
supernatants was titrated on Huh7-25-CD81 cells.
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